<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000450</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAMAS10518</org_study_id>
    <secondary_id>R01AA010518</secondary_id>
    <nct_id>NCT00000450</nct_id>
  </id_info>
  <brief_title>Naltrexone Maintenance Treatment of Alcoholism</brief_title>
  <official_title>Nalmefene Maintenance Treatment of Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term effectiveness of naltrexone
      treatment in alcohol-dependent patients who respond to short-term treatment. Those who
      respond to short-term treatment will be randomized to a 1-year, double-blind,
      placebo-controlled maintenance phase with a 6-month posttreatment followup.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>April 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <enrollment>184</enrollment>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone (Revia)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for alcohol dependence.

          -  Expresses a desire to cut down or stop drinking.

        Exclusion Criteria:

          -  Currently meets criteria for dependence on substances other than alcohol.

          -  History of opiate dependence or evidence of current opiate use.

          -  Significant medical disorders that will increase potential risk or interfere with
             study participation.

          -  Liver function tests more than 3 times normal or elevated bilirubin.

          -  Female patients who are pregnant, nursing, or not using a reliable method of birth
             control.

          -  Inability to understand and provide a consent form.

          -  Treatment with an investigational drug during the previous month.

          -  Prior treatment with naltrexone.

          -  Chronic treatment with any narcotic-containing medications during the previous month.

          -  Sensitivity to naltrexone as evidenced by adverse drug experiences especially with
             narcotic containing analgesics or opioid antagonists.

          -  Current treatment with disulfiram.

          -  More than 6 weeks of abstinence.

          -  Meets criteria for a major psychiatric disorder and is in need of, or currently
             undergoing pharmacotherapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 21, 2010</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
